Key result
Bosentan pretreatment fails to improve postischaemic cerebral hypoperfusion after transient global ischaemia.
Why the study?
The role of endogenous endothelins in mediating postischaemic hypoperfusion after transient global ischaemia was unclear.
Does Bosentan improve postischaemic hypoperfusion in rats subjected to transient global ischaemia?
Does Bosentan improve postischaemic hypoperfusion in rats subjected to transient global ischaemia?
The broad-spectrum endothelin antagonist Bosentan does not modify acute postischaemic hypoperfusion after transient global ischaemia in rats, suggesting endothelins do not play a major role in this process.
No takes yet. Share an insight, caveat, or question.
Bosentan pretreatment ineffective in this rat model; leaves open endothelin contribution to postischaemic hypoperfusion pending further studies.
Patel et al. (1996) studied Transient global ischaemia. Bosentan vs. Control was evaluated on Postischaemic hypoperfusion (cerebral blood flow). Pretreatment with the broad-spectrum endothelin antagonist Bosentan had minimal effect on postischaemic hypoperfusion in rats after transient global ischaemia.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: